Cargando…
Factors associated with development of nephrotoxicity in patients treated with vancomycin versus daptomycin for severe Gram-positive infections: A practice-based study
OBJECTIVES: To evaluate nephrotoxicity development in patients treated with vancomycin (VAN) and daptomycin (DAP) for proven severe Gram-positive infections in daily practice. PATIENTS AND METHODS: A practice-based, observational, retrospective study (eight Spanish hospitals) was performed including...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedad Española de Quimioterapia
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372966/ https://www.ncbi.nlm.nih.gov/pubmed/30630306 |
_version_ | 1783394871121281024 |
---|---|
author | Barberán, José Mensa, José Artero, Arturo Epelde, Francisco Rodriguez, Juan-Carlos Ruiz-Morales, Josefa Calleja, José-Luis Guerra, José-Manuel Martínez-Gil, Iñigo Giménez, María-José Granizo, Juan-José Aguilar, Lorenzo |
author_facet | Barberán, José Mensa, José Artero, Arturo Epelde, Francisco Rodriguez, Juan-Carlos Ruiz-Morales, Josefa Calleja, José-Luis Guerra, José-Manuel Martínez-Gil, Iñigo Giménez, María-José Granizo, Juan-José Aguilar, Lorenzo |
author_sort | Barberán, José |
collection | PubMed |
description | OBJECTIVES: To evaluate nephrotoxicity development in patients treated with vancomycin (VAN) and daptomycin (DAP) for proven severe Gram-positive infections in daily practice. PATIENTS AND METHODS: A practice-based, observational, retrospective study (eight Spanish hospitals) was performed including patients ≥18 years with a baseline glomerular filtration rate (GFR)>30 mL/min and/or serum creatinine level<2 mg/dL treated with DAP or VAN for >48h. Nephrotoxicity was considered as a decrease in baseline GRF to <50 mL/min or decrease of >10 mL/min from a baseline GRF<50 mL/min. Multivariate analyses were performed to determine factors associated with 1) treatment selection, 2) nephrotoxicity development, and 3) nephrotoxicity development within each antibiotic group. RESULTS: A total of 133 patients (62 treated with DAP, 71 with VAN) were included. Twenty-one (15.8%) developed nephrotoxicity: 4/62 (6.3%) patients with DAP and 17/71 (23.3%) with VAN (p=0.006). No differences in concomitant administration of aminoglycosides or other potential nephrotoxic drugs were found between groups. Factors associated with DAP treatment were diabetes mellitus with organ lesion (OR=7.81, 95%CI:1.39-4.35) and basal creatinine ≥0.9 mg/dL (OR=2.53, 95%CI:1.15-4.35). Factors associated with VAN treatment were stroke (OR=7.22, 95%CI:1.50-34.67), acute myocardial infarction (OR=6.59, 95%CI:1.51-28.69) and primary bacteremia (OR=5.18, 95%CI:1.03-25.99). Factors associated with nephrotoxicity (R(2)=0.142; p=0.001) were creatinine clearance<80 mL/min (OR=9.22, 95%CI:1.98-30.93) and VAN treatment (OR=6.07, 95%CI:1.86-19.93). Factors associated with nephrotoxicity within patients treated with VAN (R(2)=0.232; p=0.018) were congestive heart failure (OR=4.35, 95%CI:1.23-15.37), endocarditis (OR=7.63, 95%CI:1.02-57.31) and basal creatinine clearance<80 mL/min (OR=7.73, 95%CI:1.20-49.71). CONCLUSIONS: Nephrotoxicity with VAN was significantly higher than with DAP despite poorer basal renal status in the DAP group. |
format | Online Article Text |
id | pubmed-6372966 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Sociedad Española de Quimioterapia |
record_format | MEDLINE/PubMed |
spelling | pubmed-63729662019-03-04 Factors associated with development of nephrotoxicity in patients treated with vancomycin versus daptomycin for severe Gram-positive infections: A practice-based study Barberán, José Mensa, José Artero, Arturo Epelde, Francisco Rodriguez, Juan-Carlos Ruiz-Morales, Josefa Calleja, José-Luis Guerra, José-Manuel Martínez-Gil, Iñigo Giménez, María-José Granizo, Juan-José Aguilar, Lorenzo Rev Esp Quimioter Original OBJECTIVES: To evaluate nephrotoxicity development in patients treated with vancomycin (VAN) and daptomycin (DAP) for proven severe Gram-positive infections in daily practice. PATIENTS AND METHODS: A practice-based, observational, retrospective study (eight Spanish hospitals) was performed including patients ≥18 years with a baseline glomerular filtration rate (GFR)>30 mL/min and/or serum creatinine level<2 mg/dL treated with DAP or VAN for >48h. Nephrotoxicity was considered as a decrease in baseline GRF to <50 mL/min or decrease of >10 mL/min from a baseline GRF<50 mL/min. Multivariate analyses were performed to determine factors associated with 1) treatment selection, 2) nephrotoxicity development, and 3) nephrotoxicity development within each antibiotic group. RESULTS: A total of 133 patients (62 treated with DAP, 71 with VAN) were included. Twenty-one (15.8%) developed nephrotoxicity: 4/62 (6.3%) patients with DAP and 17/71 (23.3%) with VAN (p=0.006). No differences in concomitant administration of aminoglycosides or other potential nephrotoxic drugs were found between groups. Factors associated with DAP treatment were diabetes mellitus with organ lesion (OR=7.81, 95%CI:1.39-4.35) and basal creatinine ≥0.9 mg/dL (OR=2.53, 95%CI:1.15-4.35). Factors associated with VAN treatment were stroke (OR=7.22, 95%CI:1.50-34.67), acute myocardial infarction (OR=6.59, 95%CI:1.51-28.69) and primary bacteremia (OR=5.18, 95%CI:1.03-25.99). Factors associated with nephrotoxicity (R(2)=0.142; p=0.001) were creatinine clearance<80 mL/min (OR=9.22, 95%CI:1.98-30.93) and VAN treatment (OR=6.07, 95%CI:1.86-19.93). Factors associated with nephrotoxicity within patients treated with VAN (R(2)=0.232; p=0.018) were congestive heart failure (OR=4.35, 95%CI:1.23-15.37), endocarditis (OR=7.63, 95%CI:1.02-57.31) and basal creatinine clearance<80 mL/min (OR=7.73, 95%CI:1.20-49.71). CONCLUSIONS: Nephrotoxicity with VAN was significantly higher than with DAP despite poorer basal renal status in the DAP group. Sociedad Española de Quimioterapia 2019-02-08 2019-02 /pmc/articles/PMC6372966/ /pubmed/30630306 Text en © The Author 2019 https://creativecommons.org/licenses/by-nc/4.0/ The article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/) |
spellingShingle | Original Barberán, José Mensa, José Artero, Arturo Epelde, Francisco Rodriguez, Juan-Carlos Ruiz-Morales, Josefa Calleja, José-Luis Guerra, José-Manuel Martínez-Gil, Iñigo Giménez, María-José Granizo, Juan-José Aguilar, Lorenzo Factors associated with development of nephrotoxicity in patients treated with vancomycin versus daptomycin for severe Gram-positive infections: A practice-based study |
title | Factors associated with development of nephrotoxicity in patients treated with vancomycin versus daptomycin for severe Gram-positive infections: A practice-based study |
title_full | Factors associated with development of nephrotoxicity in patients treated with vancomycin versus daptomycin for severe Gram-positive infections: A practice-based study |
title_fullStr | Factors associated with development of nephrotoxicity in patients treated with vancomycin versus daptomycin for severe Gram-positive infections: A practice-based study |
title_full_unstemmed | Factors associated with development of nephrotoxicity in patients treated with vancomycin versus daptomycin for severe Gram-positive infections: A practice-based study |
title_short | Factors associated with development of nephrotoxicity in patients treated with vancomycin versus daptomycin for severe Gram-positive infections: A practice-based study |
title_sort | factors associated with development of nephrotoxicity in patients treated with vancomycin versus daptomycin for severe gram-positive infections: a practice-based study |
topic | Original |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372966/ https://www.ncbi.nlm.nih.gov/pubmed/30630306 |
work_keys_str_mv | AT barberanjose factorsassociatedwithdevelopmentofnephrotoxicityinpatientstreatedwithvancomycinversusdaptomycinforseveregrampositiveinfectionsapracticebasedstudy AT mensajose factorsassociatedwithdevelopmentofnephrotoxicityinpatientstreatedwithvancomycinversusdaptomycinforseveregrampositiveinfectionsapracticebasedstudy AT arteroarturo factorsassociatedwithdevelopmentofnephrotoxicityinpatientstreatedwithvancomycinversusdaptomycinforseveregrampositiveinfectionsapracticebasedstudy AT epeldefrancisco factorsassociatedwithdevelopmentofnephrotoxicityinpatientstreatedwithvancomycinversusdaptomycinforseveregrampositiveinfectionsapracticebasedstudy AT rodriguezjuancarlos factorsassociatedwithdevelopmentofnephrotoxicityinpatientstreatedwithvancomycinversusdaptomycinforseveregrampositiveinfectionsapracticebasedstudy AT ruizmoralesjosefa factorsassociatedwithdevelopmentofnephrotoxicityinpatientstreatedwithvancomycinversusdaptomycinforseveregrampositiveinfectionsapracticebasedstudy AT callejajoseluis factorsassociatedwithdevelopmentofnephrotoxicityinpatientstreatedwithvancomycinversusdaptomycinforseveregrampositiveinfectionsapracticebasedstudy AT guerrajosemanuel factorsassociatedwithdevelopmentofnephrotoxicityinpatientstreatedwithvancomycinversusdaptomycinforseveregrampositiveinfectionsapracticebasedstudy AT martinezgilinigo factorsassociatedwithdevelopmentofnephrotoxicityinpatientstreatedwithvancomycinversusdaptomycinforseveregrampositiveinfectionsapracticebasedstudy AT gimenezmariajose factorsassociatedwithdevelopmentofnephrotoxicityinpatientstreatedwithvancomycinversusdaptomycinforseveregrampositiveinfectionsapracticebasedstudy AT granizojuanjose factorsassociatedwithdevelopmentofnephrotoxicityinpatientstreatedwithvancomycinversusdaptomycinforseveregrampositiveinfectionsapracticebasedstudy AT aguilarlorenzo factorsassociatedwithdevelopmentofnephrotoxicityinpatientstreatedwithvancomycinversusdaptomycinforseveregrampositiveinfectionsapracticebasedstudy |